Message from the Guest Editors

Dear Colleagues,

Vaccination against measles, mumps, and rubella has significantly reduced these infectious diseases' incidence, mortality, and morbidity. Efforts by countries and other organizations aim to eradicate these diseases. High-quality surveillance is crucial to confirm endemic transmission and control interruption in endemic areas. While global elimination of mumps is not the primary focus, countries with high vaccine uptake have notably reduced cases. Recent mumps outbreaks among vaccinated young adults suggest vaccine immunity waning.

Genotyping and sequence analysis are vital for defining the epidemiology of these diseases and documenting transmission interruption. More precise genotyping tools like extensive sequence analysis, whole genome sequencing, and bioinformatics are needed to track transmission as we near elimination.

This Special Issue aims to collate papers that explore molecular approaches used in the global surveillance and epidemiology of measles, mumps and rubella, with varied methodologies to characterise outbreaks and define the transmission of these vaccine-preventable viruses.

Dr. Alberto Severini
Guest Editor

Joanne Hiebert
Guest Editor Assistant
Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

**Journal Rank:** JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)